サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：重症筋無力症（MG）治療市場：薬剤クラス別、年齢層別、流通チャネル別、国別、地域別 - 産業分析、市場規模、市場シェア、予測、2023-2030年
市場調査レポート
商品コード
1388792

重症筋無力症（MG）治療市場：薬剤クラス別、年齢層別、流通チャネル別、国別、地域別 - 産業分析、市場規模、市場シェア、予測、2023-2030年

Myasthenia Gravis Treatment Market, By Drug Class, By Age Group, By Distribution Channel, By Country, and By Region -Industry Analysis, Market Size, Market Share & Forecast from 2023-2030
出版日: | 発行: AnalystView Market Insights | ページ情報: 英文 303 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
重症筋無力症（MG）治療市場：薬剤クラス別、年齢層別、流通チャネル別、国別、地域別 - 産業分析、市場規模、市場シェア、予測、2023-2030年
出版日: 2023年11月01日
発行: AnalystView Market Insights
ページ情報: 英文 303 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

レポートハイライト

重症筋無力症（MG）治療市場規模は2022年に20億1,243万米ドルとなり、2023年から2030年にかけてCAGR 9.4％で拡大

重症筋無力症（MG）は、頭部、眼球、四肢、脊髄、呼吸筋の筋力低下を引き起こす、慢性でまれな進行性の神経筋疾患の一種です。これらの自己免疫疾患では、神経から筋肉への適切な電気信号伝達を妨げるアセチルコリン受容体（AchR）に対する抗体が産生されます。さらに、顔面神経麻痺、眼瞼下垂、複視、歩行困難などは重症筋無力症（MG）の症状です。これらの疾患は、抗体の血液検査、磁気共鳴画像法（MRI）、エドロホニウム検査、反復神経刺激検査、コンピューター断層撮影法（CT）など、数多くの検査によって診断されます。

重症筋無力症（MG）治療市場-市場力学

重症筋無力症（MG）の世界の有病率の上昇と認知度の向上が市場成長を牽引

重症筋無力症（MG）の世界の罹患率の上昇、重症筋無力症（MG）の革新的な治療法の採用、早期診断に関する知識の増加は、重症筋無力症（MG）治療市場の発展を促進する主な要因です。さらに、疾患治療のための新薬開発に製薬企業が注力するようになったことが、重症筋無力症（MG）治療市場の著しい成長を目の当たりにしています。さらに、免疫抑制剤やモノクローナル抗体を含むさまざまな薬剤が、重症筋無力症（MG）の治療における有効性を試験・開発されています。しかし、重症筋無力症（MG）の治療に使用される薬剤に関連する副作用が、間もなく市場の成長を抑制すると予想されています。さらに、医療専門家や患者の間で重症筋無力症（MG）に対する認識が高まっていることが、効果的な治療法に対する需要の増加に大きく寄与しています。これに伴い、重症筋無力症（MG）の徴候やリスクについてより多くの人が認識するようになり、個人が重症筋無力症（MG）の治療や診断を受ける可能性が高まっています。また、医療の専門家も重症筋無力症（MG）とその治療法に関する知識を深め、効率的な治療法に対する需要が高まっています。

重症筋無力症（MG）に関する意識を高め、医療のインフラを改善するための政府の取り組みが、市場の成長に拍車をかけています。

重症筋無力症（MG）治療市場-セグメンテーション分析：

重症筋無力症（MG）治療の世界市場は、薬剤クラス別、年齢層別、流通チャネル別、地域別に区分されます。

薬剤クラス別では、胸腺摘出術、モノクローナル抗体、コリンエステラーゼ阻害薬、迅速免疫療法、慢性免疫調節薬、その他の5つに分類されます。モノクローナル抗体セグメントは、重症筋無力症（MG）の治療における高い精度と有効性の向上により、最も高い市場シェアを占めると予想されます。モノクローナル抗体の使用が増加しているのは、生涯にわたる副腎皮質ステロイドへの曝露を減らし、長期的な結果を改善するためです。

市場は流通チャネルによって、ドラッグストアや小売薬局、病院薬局、オンラインプロバイダーの3つに分類されます。病院内薬局は、予測期間中もその優位性を維持すると思われます。このセグメントは、高度な機器に対する高い需要と、病院でのMG治療のための大規模な患者プールへのアクセスに起因しています。さらに、このような施設では幅広い治療オプションが利用可能であるため、治療や診断のための患者の訪問が増加しています。最先端の医療インフラへの投資が増加していることも、大きなシェアを占める主な要因です。

重症筋無力症（MG）治療市場-地理的洞察

地理的に、この市場は北米、ラテンアメリカ、欧州、アジア太平洋、中東アフリカの地域に分析されます。これらの地域は、ビジネスをもたらす国によってさらに細分化されます。重症筋無力症（MG）治療の市場シェアは北米が最も高いです。自己免疫疾患の評価における成長、革新的な医薬品を提供する重要な企業の存在、重症筋無力症（MG）の高い発生率、改善された医療インフラへのアクセスなどが、重症筋無力症（MG）治療業界を牽引すると予想されています。さらに、アジア太平洋地域は、自己免疫疾患と利用可能な治療オプションに関する啓発キャンペーンの増加、自己免疫疾患の増加、重症筋無力症（MG）の効果的な治療オプションの開発のための投資の増加により、顕著な成長を示すと予測されます。また、新興国における医療支出の急増は、市場拡大のための有利な機会を提供し、重症筋無力症（MG）治療市場を牽引すると予測されています。

重症筋無力症（MG）治療市場-競合情勢：

政府のようないくつかの組織は、自己免疫疾患に関する個人へのカウンセリングを行っています。eコマースは、従来の購入方法と比較してオンラインショッピングを好む消費者の増加により、世界中の大企業や中小企業にとって不可欠なツールとなっています。さらに、医薬品の使用法や重症筋無力症（MG）について人々を教育するための健康アプリを通じたいくつかのアニメーションが、重症筋無力症（MG）治療市場の成長に寄与しています。さらに、主要な市場プレーヤーは、重症筋無力症（MG）治療業界の製品ポートフォリオを強化するための主要な開発戦略として、戦略的提携、買収、製品承認、拡大、および合意を採用しています。例えば、2021年3月、世界中の人々の健康と幸福を向上させる世界医療企業であるGrifols社は、幅広い免疫グロブリンを生成する新規の方法を後押しするためにGigaGen Inc.を買収すると発表しました。

目次

第1章 重症筋無力症（MG）治療市場概要

  • 調査範囲
  • 市場推定年数

第2章 エグゼクティブサマリー

  • 市場内訳
  • 競合考察

第3章 重症筋無力症（MG）治療の主要な市場動向

  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 今後の市場動向

第4章 重症筋無力症（MG）治療産業の調査

  • PEST分析
  • ポーターのファイブフォース分析
  • 成長見通しのマッピング
  • 規制枠組みの分析

第5章 重症筋無力症（MG）治療市場：COVID-19の影響分析

  • COVID-19以前の影響分析
  • COVID-19以後の影響分析

第6章 重症筋無力症（MG）治療市場情勢

  • 重症筋無力症（MG）治療市場シェア分析、2022年
  • 主要メーカー別の内訳データ
    • 既存企業の分析
    • 新興企業の分析

第7章 重症筋無力症（MG）治療市場：薬剤クラス別

  • 概要
    • 薬剤クラス別のセグメントシェア分析
    • 胸腺切除術
    • モノクローナル抗体
    • コリンエステラーゼ阻害剤
    • 迅速免疫療法
    • 慢性免疫調節薬
    • その他

第8章 重症筋無力症（MG）治療市場：年齢層別

  • 概要
    • 年齢層別のセグメントシェア分析
    • 55歳未満
    • 55歳以上

第9章 重症筋無力症（MG）治療市場：流通チャネル別

  • 概要
    • 販売チャネル別のセグメントシェア分析
    • ドラッグストア・小売薬局
    • 病院薬局
    • オンラインプロバイダー

第10章 重症筋無力症（MG）治療市場：地域別

  • イントロダクション
  • 北米
    • 概要
    • 北米の主要メーカー
    • 米国
    • カナダ
  • 欧州
    • 概要
    • 欧州の主要メーカー
    • ドイツ
    • イタリア
    • 英国
    • フランス
    • ロシア
    • オランダ
    • スウェーデン
    • ポーランド
    • その他
  • アジア太平洋（APAC）
    • 概要
    • アジア太平洋地域の主要メーカー
    • インド
    • 中国
    • 日本
    • 韓国
    • オーストラリア
    • タイ
    • インドネシア
    • フィリピン
    • その他
  • ラテンアメリカ
    • 概要
    • ラテンアメリカの主要メーカー
    • ブラジル
    • メキシコ
    • アルゼンチン
    • コロンビア
    • その他
  • 中東とアフリカ
    • 概要
    • 中東とアフリカの主要メーカー
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • トルコ
    • アルジェリア
    • エジプト
    • その他

第11章 主要ベンダー分析：重症筋無力症（MG）治療産業

  • 競合ダッシュボード
  • 企業プロファイル
    • F.Hoffmann-La Roche AG
    • Alexion Pharmaceutical Inc.
    • Zydus Lifesciences Limited
    • Grifols SA
    • Shire plc
    • Kedrion
    • Avadel Pharmaceuticals, Plc.
    • Octapharma AG
    • Novartis
    • Bausch Health Companies Inc.
    • Pfizer, Inc.
    • AbbVie Inc.
    • GlaxoSmithKline Plc.

第12章 アナリストの全方位展望

図表

List of Tables

  • TABLE List of data sources
  • TABLE Market drivers; Impact Analysis
  • TABLE Market restraints; Impact Analysis
  • TABLE Myasthenia Gravis Treatment Market: Drug Class Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Drug Class
  • TABLE Global Myasthenia Gravis Treatment Market, by Drug Class2018-2030 (USD Million)
  • TABLE Myasthenia Gravis Treatment Market: Age GroupSnapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Age Group
  • TABLE Global Myasthenia Gravis Treatment Market, by Age Group2018-2030 (USD Million)
  • TABLE Myasthenia Gravis Treatment Market: Distribution Channel Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Distribution Channel
  • TABLE Global Myasthenia Gravis Treatment Market, by Distribution Channel 2018-2030 (USD Million)
  • TABLE Myasthenia Gravis Treatment Market: Regional snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Region
  • TABLE Global Myasthenia Gravis Treatment Market, by Region 2018-2030 (USD Million)
  • TABLE North America Myasthenia Gravis Treatment Market, by Country, 2018-2030 (USD Million)
  • TABLE North America Myasthenia Gravis Treatment Market, by Drug Class, 2018-2030 (USD Million)
  • TABLE North America Myasthenia Gravis Treatment Market, by Age Group, 2018-2030 (USD Million)
  • TABLE North America Myasthenia Gravis Treatment Market, by Distribution Channel, 2018-2030 (USD Million)
  • TABLE Europe Myasthenia Gravis Treatment Market, by Country, 2018-2030 (USD Million)
  • TABLE Europe Myasthenia Gravis Treatment Market, by Drug Class, 2018-2030 (USD Million)
  • TABLE Europe Myasthenia Gravis Treatment Market, by Age Group, 2018-2030 (USD Million)
  • TABLE Europe Myasthenia Gravis Treatment Market, by Distribution Channel, 2018-2030 (USD Million)
  • TABLE Asia Pacific Myasthenia Gravis Treatment Market, by Country, 2018-2030 (USD Million)
  • TABLE Asia Pacific Myasthenia Gravis Treatment Market, by Drug Class, 2018-2030 (USD Million)
  • TABLE Asia Pacific Myasthenia Gravis Treatment Market, by Age Group, 2018-2030 (USD Million)
  • TABLE Asia Pacific Myasthenia Gravis Treatment Market, by Distribution Channel, 2018-2030 (USD Million)
  • TABLE Latin America Myasthenia Gravis Treatment Market, by Country, 2018-2030 (USD Million)
  • TABLE Latin America Myasthenia Gravis Treatment Market, by Drug Class, 2018-2030 (USD Million)
  • TABLE Latin America Myasthenia Gravis Treatment Market, by Age Group, 2018-2030 (USD Million)
  • TABLE Latin America Myasthenia Gravis Treatment Market, by Distribution Channel, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Myasthenia Gravis Treatment Market, by Country, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Myasthenia Gravis Treatment Market, by Drug Class, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Myasthenia Gravis Treatment Market, by Age Group, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Myasthenia Gravis Treatment Market, by Distribution Channel, 2018-2030 (USD Million)

List of Figures

  • FIGURE Myasthenia Gravis Treatment Market Segmentation
  • FIGURE Market research methodology
  • FIGURE Value chain analysis
  • FIGURE Porter's Five Forces Analysis
  • FIGURE Market Attractiveness Analysis
  • FIGURE COVID-19 Impact Analysis
  • FIGURE Pre & Post COVID-19 Impact Comparision Study
  • FIGURE Competitive Landscape; Key company market share analysis, 2022
  • FIGURE Drug Class segment market share analysis, 2022&2030
  • FIGURE Drug Class segment market size forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Age Group segment market share analysis, 2022&2030
  • FIGURE Age Group segment market size forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Distribution Channel segment market share analysis, 2022&2030
  • FIGURE Distribution Channel segment market size forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Regional segment market share analysis, 2022&2030
  • FIGURE Regional segment market size forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE North America Myasthenia Gravis Treatment Market share and leading players, 2022
  • FIGURE Europe Myasthenia Gravis Treatment Market share and leading players, 2022
  • FIGURE Asia Pacific Myasthenia Gravis Treatment Market share and leading players, 2022
  • FIGURE Latin America Myasthenia Gravis Treatment Market share and leading players, 2022
  • FIGURE Middle East and Africa Myasthenia Gravis Treatment Market share and leading players, 2022
  • FIGURE North America market share analysis by country, 2022
  • FIGURE U.S. Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Canada Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Europe Myasthenia Gravis Treatment Market share analysis by country, 2022
  • FIGURE Germany Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Spain Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Italy Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE France Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE UK Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Russia Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Netherlands Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Sweden Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Poland Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Rest of the Europe Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Asia Pacific Myasthenia Gravis Treatment Market share analysis by country, 2022
  • FIGURE India Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE China Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Japan Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE South Korea Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Australia Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Thailand Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Indonesia Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Phillipines Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Rest of APAC Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Latin America Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Latin America Myasthenia Gravis Treatment Market share analysis by country, 2022
  • FIGURE Brazil Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Mexico Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Argentina Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Colombia Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Rest of LATAM Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Middle East and Africa Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Middle East and Africa Myasthenia Gravis Treatment Market share analysis by country, 2022
  • FIGURE Saudi Arabia Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE United Arab Emirates Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Israel Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Turkey Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Algeria Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Egypt Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Rest of MEA Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
目次
Product Code: ANV1846

REPORT HIGHLIGHT

Myasthenia gravis treatment market size was valued at USD 2,012.43 Million in 2022, expanding at a CAGR of 9.4% from 2023 to 2030.

Myasthenia gravis (MG) is a type of chronic, rare, and progressive neuromuscular disorder that causes weakness of the head, eye, limb, spinal, and respiratory muscles. Antibodies against the acetylcholine receptor (AchR) that prevent proper electrical signal transmission from nerves to muscles are produced in these autoimmune disorders. Additionally, facial paralysis, drooping of eyelids, double vision, and difficulty in walking are symptoms of myasthenia gravis. These diseases are diagnosed by numerous tests including blood tests for antibodies, Magnetic Resonance Imaging (MRI), edrophonium test, repetitive nerve stimulation test, and Computed Tomography (CT).

Myasthenia Gravis Treatment Market- Market Dynamics

Rising prevalence and increasing awareness about myasthenia gravis worldwide driving the market growth

The rising global incidence of myasthenia gravis, the adoption of innovative treatments for myasthenia gravis, and increased knowledge about early diagnosis are the primary drivers driving the development of the myasthenia gravis treatment market. Moreover, the growing focus of pharmaceutical companies on the development of novel drugs for disease treatment is witnessing significant growth in the myasthenia gravis treatment market. Additionally, various medications, including immunosuppressants and monoclonal antibodies, are being tested and developed for their efficacy in treating myasthenia gravis. However, side effects associated with the drugs used for treating myasthenia gravis are expected to restrain the market growth shortly. Furthermore, rising awareness about myasthenia gravis among healthcare professionals and patients is majorly contributing to the increase in demand for effective treatments. In line with this, individuals are more likely to seek treatment and diagnosis for myasthenia gravis as more people become aware of its signs and risks. Healthcare professionals are also becoming more knowledgeable about the disease and its available treatments, leading to an increased demand for efficient treatments.

Myasthenia Gravis Treatment Market- Key Insights

  • As per the analysis shared by our research analyst, the global myasthenia gravis treatment market is estimated to grow annually at a CAGR of around 9.4% over the forecast period (2023-2030)
  • The myasthenia gravis treatment industry is projected to grow at a significant rate due to the rising awareness about myasthenia gravis among healthcare professionals and patients
  • Based on drug class segmentation, monoclonal antibodies was predicted to show maximum market share in the year 2022
  • Based on distribution channel segmentation, hospital pharmacies was the leading type in 2022

Government initiatives to increase consciousness regarding myasthenia gravis and improve healthcare infrastructure are fueling the market growth.

Myasthenia Gravis Treatment Market- Segmentation Analysis:

The global myasthenia gravis treatment market is segmented on the basis of drug class, age group, distribution channel, and region.

The market is divided into five categories based on drug class: thymectomy, monoclonal antibodies, cholinesterase inhibitors, rapid immunotherapies, chronic immunomodulators, and others. The monoclonal antibodies segment is expected to hold the highest market share due to the high precision in treating myasthenia gravis and improved efficacy. The rising use of monoclonal antibodies aims to reduce lifelong exposure to corticosteroids and improve long-term results.

The market is divided into three categories based on distribution channels: drugstore and retail pharmacies, hospital pharmacies, and online providers. The hospital pharmacies segment is likely to maintain its dominance over the forecast period. The segment is attributed to access to the high demand for advanced equipment and a large patient pool for MG treatment in hospital settings. Additionally, the availability of a broad range of treatment options in such facilities has increased patient visits for treatment and diagnosis. The rising investment in state-of-the-art healthcare infrastructures is the prime factor contributing to its large share.

Myasthenia Gravis Treatment Market- Geographical Insights

Geographically, this market is analyzed into the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further segmented as per the nations bringing business. North America has the biggest market share for myasthenia gravis therapy. The growth in autoimmune disease evaluation, the existence of significant companies providing innovative medicines, the high incidence of myasthenia gravis, and the accessibility of improved healthcare infrastructure are all expected to drive the myasthenia gravis treatment industry. Moreover, Asia-Pacific is accounted to witness notable growth due to the increase in awareness campaigns regarding autoimmune diseases & available treatment options, rising number of autoimmune diseases, and rising investments for the development of effective treatment options for myasthenia gravis. In addition, in emerging economies upsurge in healthcare expenditure is anticipated to provide lucrative opportunities for market expansion, driving the myasthenia gravis treatment market.

Myasthenia Gravis Treatment Market- Competitive Landscape:

Several organizations such as the government are counseling individuals regarding autoimmune diseases. E-commerce has become a vital tool for large and small businesses across the globe, due to the increase in the preference of consumers for online shopping as compared to traditional purchasing methods. Additionally, several animations through health apps to educate people regarding the usage of medications and myasthenia gravis have contributed toward the myasthenia gravis treatment market growth. Moreover, major market players have adopted strategic alliance, acquisition, product approval, expansion, and agreement as key developmental strategies to enhance the product portfolio of the myasthenia gravis treatment industry. For instance, in March 2021, Grifols a global healthcare company to improve the health and well-being of people worldwide announced to acquire GigaGen Inc. to boost a novel method to generate a broad range of immunoglobulins.

Recent Developments:

For instance, in April 2023, CSL Behring, a global biotechnology company, has received FDA approval for a 50mL/10gm prefilled syringe for Hizentra. CSL Behring offers a comprehensive variety of prefilled syringe sizes to satisfy the specific needs of persons suffering from Primary Immunodeficiency as well as Chronic Inflammatory Demyelinating Polyneuropathy.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET KEY PLAYERS

  • F.Hoffmann-La Roche AG
  • Alexion Pharmaceutical Inc.
  • Zydus Lifesciences Limited
  • Grifols SA
  • Shire plc
  • Kedrion
  • Avadel Pharmaceuticals, Plc.
  • Octapharma AG
  • Novartis
  • Bausch Health Companies Inc.
  • Pfizer, Inc.
  • AbbVie Inc.
  • GlaxoSmithKline Plc.

GLOBALMYASTHENIA GRAVIS TREATMENT MARKET, BY DRUG CLASS

  • Thymectomy
  • Monoclonal Antibodies
  • Cholinesterase Inhibitors
  • Rapid Immunotherapies
  • Chronic Immunomodulators
  • Others

GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET, BY AGE GROUP

  • Below 55 years
  • Above 55 years

GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL

  • Drug store and retail pharmacies
  • Hospital pharmacies
  • Online providers

GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET, BY REGION

  • North America
    • The U.S.
    • Canada
  • Europe
    • Germany
    • France
    • Italy
    • Spain
    • United Kingdom
    • Russia
    • Netherlands
    • Sweden
    • Poland
    • Rest of Europe
  • Asia Pacific
    • India
    • China
    • South Korea
    • Japan
    • Australia
    • Thailand
    • Indonesia
    • Philippines
    • Rest of APAC
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Colombia
    • Rest of LATAM
  • The Middle East and Africa
    • Saudi Arabia
    • United Arab Emirates
    • Israel
    • Turkey
    • Algeria
    • Egypt
    • Rest of MEA

Table of Contents

1. Myasthenia Gravis Treatment Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Myasthenia Gravis Treatment Market Snippet by Drug Class
    • 2.1.2. Myasthenia Gravis Treatment Market Snippet by Age Group
    • 2.1.3. Myasthenia Gravis Treatment Market Snippet by Distribution Channel
    • 2.1.4. Myasthenia Gravis Treatment Market Snippet by Country
    • 2.1.5. Myasthenia Gravis Treatment Market Snippet by Region
  • 2.2. Competitive Insights

3. Myasthenia Gravis Treatment Key Market Trends

  • 3.1. Myasthenia Gravis Treatment Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Myasthenia Gravis Treatment Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Myasthenia Gravis Treatment Market Opportunities
  • 3.4. Myasthenia Gravis Treatment Market Future Trends

4. Myasthenia Gravis Treatment Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Myasthenia Gravis Treatment Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Myasthenia Gravis Treatment Market Landscape

  • 6.1. Myasthenia Gravis Treatment Market Share Analysis, 2022
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Myasthenia Gravis Treatment Market - By Drug Class

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Drug Class, 2022&2030 (%)
    • 7.1.2. Thymectomy
    • 7.1.3. Monoclonal Antibodies
    • 7.1.4. Cholinesterase Inhibitors
    • 7.1.5. Rapid Immunotherapies
    • 7.1.6. Chronic Immunomodulators
    • 7.1.7. Others

8. Myasthenia Gravis Treatment Market - By Age Group

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Age Group, 2022&2030 (%)
    • 8.1.2. Below 55 years
    • 8.1.3. Above 55 years

9. Myasthenia Gravis Treatment Market - By Distribution Channel

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Distribution Channel, 2022&2030 (%)
    • 9.1.2. Drug store and retail pharmacies
    • 9.1.3. Hospital pharmacies
    • 9.1.4. Online providers

10. Myasthenia Gravis Treatment Market- By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2022&2030 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. Myasthenia Gravis Treatment Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. Myasthenia Gravis Treatment Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.8. Italy
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.8.3. Italy Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.3.8.4. Italy Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.3.8.5. Italy Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.9. United Kingdom
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.9.3. United Kingdom Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.3.9.4. United Kingdom Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.3.9.5. United Kingdom Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.10. France
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.10.3. France Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.3.10.4. France Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.3.10.5. France Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.11. Russia
      • 10.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.11.2. Russia Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.3.11.3. Russia Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.3.11.4. Russia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.12. Netherlands
      • 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.12.2. Netherlands Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.3.12.3. Netherlands Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.3.12.4. Netherlands Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.13. Sweden
      • 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.13.2. Sweden Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.3.13.3. Sweden Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.3.13.4. Sweden Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.14. Poland
      • 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.14.2. Poland Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.3.14.3. Poland Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.3.14.4. Poland Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.15. Rest of Europe
      • 10.3.15.1. Overview
      • 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.15.3. Rest of the Europe Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.3.15.4. Rest of the Europe Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.3.15.5. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. Myasthenia Gravis Treatment Key Manufacturers in Asia Pacific
    • 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.4.4. Asia Pacific Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.4.5. Asia Pacific Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
    • 10.4.6. Asia Pacific Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.7. India
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.7.3. India Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.4.7.4. India Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.4.7.5. India Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.8. China
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.8.3. China Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.4.8.4. China Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.4.8.5. China Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.9. Japan
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.9.3. Japan Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.4.9.4. Japan Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.4.9.5. Japan Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.10. South Korea
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.10.3. South Korea Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.4.10.4. South Korea Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.4.10.5. South Korea Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.12. Thailand
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.12.3. Thailand Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.4.12.4. Thailand Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.4.12.5. Thailand Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.13. Indonesia
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.13.3. Indonesia Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.4.13.4. Indonesia Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.4.13.5. Indonesia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.15. Rest of APAC
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.15.3. Rest of APAC Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.4.15.4. Rest of APAC Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.4.15.5. Rest of APAC Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.5. Latin America
    • 10.5.1. Overview
    • 10.5.2. Myasthenia Gravis Treatment Key Manufacturers in Latin America
    • 10.5.3. Latin America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.5.4. Latin America Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.5.5. Latin America Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
    • 10.5.6. Latin America Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.6. Middle East and Africa
    • 10.6.1. Overview
    • 10.6.2. Myasthenia Gravis Treatment Key Manufacturers in Middle East and Africa
    • 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.6.4. Middle East and Africa Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.6.5. Middle East and Africa Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
    • 10.6.6. Middle East and Africa Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.8. United Arab Emirates
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.8.3. United Arab Emirates Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.6.8.4. United Arab Emirates Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.6.8.5. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.13. Rest of MEA
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.13.3. Rest of MEA Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.6.13.4. Rest of MEA Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.6.13.5. Rest of MEA Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)

11. Key Vendor Analysis- Myasthenia Gravis Treatment Industry

  • 11.1. Competitive Dashboard
  • 11.2. Company Profiles
    • 11.2.1. F.Hoffmann-La Roche AG
    • 11.2.2. Alexion Pharmaceutical Inc.
    • 11.2.3. Zydus Lifesciences Limited
    • 11.2.4. Grifols SA
    • 11.2.5. Shire plc
    • 11.2.6. Kedrion
    • 11.2.7. Avadel Pharmaceuticals, Plc.
    • 11.2.8. Octapharma AG
    • 11.2.9. Novartis
    • 11.2.10. Bausch Health Companies Inc.
    • 11.2.11. Pfizer, Inc.
    • 11.2.12. AbbVie Inc.
    • 11.2.13. GlaxoSmithKline Plc.

12. 360 Degree Analyst View

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us